Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing Agenus Inc.’s immuno-oncology disclosures can feel like decoding lab notebooks—hundreds of pages packed with trial endpoints, milestone payments, and manufacturing risks. If you’ve ever wondered how to locate breakthrough data or track executive stock sales before a catalyst, you’re not alone.
Stock Titan delivers AI-powered summaries that turn every Agenus SEC document into plain English. Whether you need the Agenus quarterly earnings report 10-Q filing for burn-rate analysis, an Agenus 8-K material events explained alert on new clinical results, or Agenus insider trading Form 4 transactions to monitor buying and selling, our platform updates in real time as soon as EDGAR posts.
Here’s how investors use it:
- Receive push notifications for Agenus Form 4 insider transactions real-time and spot buying patterns.
- Dive into an Agenus annual report 10-K simplified view that highlights cash runway, collaboration revenue, and cGMP manufacturing commitments.
- Compare pipeline progress across quarters with succinct Agenus earnings report filing analysis.
- Access the latest Agenus proxy statement executive compensation details without sifting through appendices.
Every filing—10-K, 10-Q, 8-K, S-1, and more—is indexed, searchable, and paired with concise expert context, ensuring understanding Agenus SEC documents with AI is straightforward. No more scrolling through dense scientific jargon; the critical insights are surfaced for you.
Agenus (Nasdaq: AGEN) filed an 8-K detailing the results of its 17 June 2025 Annual Meeting, where 16.71 million shares—61.5 % of shares outstanding—were represented.
Board elections: Class I directors Brian Corvese (5.99 m for / 4.83 m withheld) and Timothy Wright (6.86 m for / 3.96 m withheld) were elected to serve until 2028.
Equity & compensation matters:
- Stockholders approved expanding the 2019 Equity Incentive Plan to 12.05 m shares, adding 7.0 m shares (6.14 m for / 4.59 m against / 0.08 m abstain).
- They approved raising share limits on the Directors’ Deferred Compensation Plan (+25 k shares) and the 2019 ESPP (+50 k shares).
- A one-time option exchange was rejected (4.87 m for / 5.82 m against).
- The advisory say-on-pay resolution was also rejected (5.16 m for / 5.18 m against).
Audit: KPMG LLP was ratified for FY 2025 (13.62 m for / 2.87 m against).
The voting pattern shows notable shareholder resistance to current compensation practices—even as additional share reserves for future equity awards were endorsed—signalling potential governance scrutiny ahead.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
